Davi Luxury Brand (MDAV) 10-Q 7 Feb 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Dec. 31, 2013	Feb. 07, 2014
Document And Entity Information	'	'
Entity Registrant Name	'Davi Luxury Brand Group, Inc.	'
Entity Central Index Key	'0001450552	'
Document Type	'10-Q	'
Document Period End Date	31-Dec-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--09-30	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	14,145,917
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Sep. 30, 2013
Current assets:	'	'
Cash	$529,526	$654,346
Accounts receivable, net	70,450	76,234
Inventory, net	39,980	5,952
Other assets	2,566	3,585
Total current assets	642,522	740,117
Property and equipment, net	57,047	51,809
Intangible assets, net	68,301	69,447
Security deposit	10,596	10,596
Total assets	778,466	871,969
Current liabilities:	'	'
Accounts payable and accrued expenses	89,694	26,876
Accounts payable - related party	127,900	119,500
Common stock payable	0	95,010
Deferred revenue	173,797	183,250
Total current liabilities	391,391	424,636
Deferred lease	2,750	2,330
Total liabilities	394,141	426,966
Stockholders equity:	'	'
Common stock, $0.001 par value; 75,000,000 shares authorized;14,145,917 and 13,195,917 shares issued and outstanding at December 31, 2013 and September 30, 2013, respectively	14,146	13,196
Additional paid-in capital	1,913,942	1,791,315
Accumulated deficit	-1,543,763	-1,359,508
Total stockholders equity	384,325	445,003
Total liabilities and stockholders equity	$778,466	$871,969

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Sep. 30, 2013
Statement of Financial Position [Abstract]	'	'
Common stock par value	$0.00	$0.00
Common stock shares authorized	75,000,000	75,000,000
Common stock shares issued	14,145,917	13,195,917
Common stock shares outstanding	14,145,917	13,195,917

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Sales	'	'
Royalty revenues	$79,453	$127,183
Product sales	3,658	27,478
Total sales	83,111	154,661
Cost of goods sold	1,087	6,886
Gross profit	82,024	147,775
Operating expenses:	'	'
Wages and professional fees	203,675	104,818
Product development	0	1,640
General and administrative	62,604	68,931
Total operating expenses	266,279	175,389
Loss from operations	-184,255	-27,614
Other expense	'	'
Interest expense	0	5,403
Total other expense	0	5,403
Net loss	($184,255)	($33,017)
Weighted average number of common shares outstanding - basic and diluted	13,443,200	9,284,117
Net loss per share - basic and diluted	($0.01)	$0

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities	'	'
Net loss	($184,255)	($33,017)
Adjustments to reconcile net loss to net cash provided by (used in) provided by operating activities	'	'
Depreciation and amortization	8,438	4,699
Stock based compensation	28,567	0
Amortization of debt discount	0	5,000
Changes in operating assets and liabilities	'	'
Accounts receivable	5,784	50,943
Inventory	-34,028	1,565
Other assets	1,019	-4,940
Accounts payable and accrued expenses	62,818	9,931
Accounts payable - related parties	8,400	4,000
Deferred revenue	-9,453	6,968
Deferred lease	420	-663
Net cash provided by (used in) provided by operating activities	-112,290	44,486
Purchase of fixed assets	-12,530	-8,825
Net cash used in investing activities	-12,530	-8,825
Net change in cash	-124,820	35,661
Cash, beginning of period	654,346	346,699
Cash, end of period	529,526	382,360
Supplemental disclosure of cash flow information:	'	'
Income taxes paid	0	0
Interest paid	0	0
Supplemental disclosure of non-cash flow investing and financing activities:	'	'
Common stock issued for common stock payable	$95,010	$0

ORGANIZATION_AND_NATURE_OF_OPE

ORGANIZATION AND NATURE OF OPERATIONS	3 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
ORGANIZATION AND NATURE OF OPERATIONS	'
	Note 1 ORGANIZATION AND NATURE OF OPERATIONS
	Davi Luxury Brand Group, Inc. (“we,” “us,” “our,” “DAVI”, or the “Company”) was incorporated in the State of Nevada on July 26, 2007.   We have developed and are expanding our skin care line/cosmetics business based on a series of grape and botanical-based luxury branded skin care products marketed under the “DAVI”, “DAVI SKIN” and “DAVI NAPA” brand names. Directly, or through our licensees, we have developed and currently market a line of high quality skin care products that are sold as prestige products principally through high-end distribution channels to complement the prestige images associated with the DAVI, DAVI SKIN and DAVI NAPA brands. We are currently targeting high-end retail stores, luxury hotels, and in-flight and duty-free shops of global luxury airlines in order to establish our brand as a luxury product used in first class locations. Our goal is to expand the targeted scope of our sales efforts with respect to upscale department stores and specialty retailers. In addition, our Le Grand Cru collection of products are available for sale through our www.daviskin.com website, and we expect to offer additional products online through out fiscal 2014.
	On September 4, 2012, we entered into a Brand and Trademark License Agreement (the “LGHH License Agreement”) with LG Household and Health Care, Ltd. (“LGHH”). Under the LGHH License Agreement, we granted LGHH an exclusive license to manufacture, sell, market and distribute in Korea, Japan, China and other Asian markets DAVI branded skin care, cosmetics, hair care and other products including the right to develop retail outlets and other commercial ventures in the Asian-Pacific region. LGHH commenced sales of DAVI products in fiscal 2013 with the opening of four new DAVI retail stores in Seoul, Korea that are dedicated to the sale of DAVI branded skincare and cosmetic products. Under the 10-year LGHH License Agreement, LGHH has agreed to pay us a royalty based on the DAVI branded products that it sells in the licensed territory. During fiscal 2013, we collaborated with LGHH's research and development team to create a new skincare product line utilizing LGHH's advanced technology along with our exclusive Meritage™ Blend and the patented Phytosphere technology - "Phyto-Meritage™" that we use for our products. A full line of these skin care products has now been developed and commercially released in Asia, as well as, in the U.S. on our www.daviskin.com website.
	The LGHH License Agreement grants LGHH the right to commercialize DAVI branded women's and men's skincare and cosmetics, including the development of retail outlets and other commercial ventures, in the Asian-Pacific region.  LGHH commenced sales of DAVI products in fiscal 2013 with the opening of four new DAVI retail stores in Seoul, South Korea that are dedicated  to the sale of DAVI branded skincare and cosmetic products.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	Note 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	In the opinion of management, the accompanying unaudited interim financial statements contain all adjustments necessary to present fairly the Company’s financial position as of December 31, 2013, and the results of operations and cash flows for the three months ended December 31, 2013 and 2012. The adjustments made are of a normal recurring nature. The accompanying unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The operating results for the three months ended December 31, 2013 are not necessarily indicative of the results that may be expected for the year ending September 30, 2014. The accompanying unaudited financial statements should be read in conjunction with the audited financial statements for the year ended September 30, 2013, which are included in our Annual Report on Form 10-K, and the "risk factors" described therein.
	Reclassifications
	For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the financial statement presentation used in fiscal 2014. These reclassifications have no impact on net loss.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Dec. 31, 2013
RELATED PARTY TRANSACTIONS	'
	Note 3 RELATED PARTY TRANSACTIONS
	In order to preserve cash for other working capital needs, Parrish Medley, the Company’s Chief Executive Officer, agreed to accrue a portion of the amounts owed to him under his employment agreement. As of December 31, 2013, the Company owed $127,900 for such accrued wages.
	On March 11, 2013, the Company entered into a new consulting agreement with Carlo Mondavi, a shareholder and former Chairman of the Board, to provide various services for the Company related to the development and marketing of its products, the Company’s public image, its brand recognition and other public relation matters (the “Agreement”). The Agreement supersedes all prior and existing negotiations and agreements between the Company and Mr. Mondavi and both parties agreed that Mr. Mondavi’s previous consulting agreement with the Company has been terminated and that neither party has any financial obligation to the other party under the previous agreement. In accordance with the Agreement, Mr. Mondavi is to be paid $5,000 per month, plus reasonable out-of-pocket expenses. The Agreement expires on March 11, 2015 unless terminated earlier by either party upon 30 days written notice.

CUSTOMER_CONCENTRATIONS

CUSTOMER CONCENTRATIONS	3 Months Ended
	Dec. 31, 2013
CUSTOMER CONCENTRATIONS	'
	Note 4 CUSTOMER CONCENTRATIONS
	During the three months ended December 31, 2013 and 2012, 84% and 71%, respectively, of our sales were generated from royalty revenues under a license agreement to provide DAVI branded products to passengers of Korean Air. The Company’s reliance on this licensing agreement makes us vulnerable to the risk of a near-term severe impact. Should the licensee terminate the license agreement, our financial condition could be materially and adversely affected, and our on-going operations could be severely hampered. Included in accounts receivable at December 31, 2013 was approximately $70,000 owed under this license agreement.

EQUITY

EQUITY	3 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
EQUITY	'
	Note 5 EQUITY
	Common Stock
	During the fiscal year ended September 30, 2013, the Company (i) received proceeds of $75,010 from accredited investors for the purchase of 750,000 shares of common stock, and (ii) granted 200,000 shares of common stock as payment in full to a consultant for services valued at $20,000. However, these shares were not issued until the first quarter of fiscal 2014.
	Common Stock Warrants
	Since inception, the Company has issued warrants to purchase shares of the Company’s common stock to accredited investors. A summary of the Company’s warrants activity and related information for the three months ended December 31, 2013 is provided below:
	Warrant Activity Table:
				Number of
				Warrants
	Outstanding at September 30, 2013				1,875,000
	Warrants exercised				-
	Warrants granted				-
	Warrants expired				-
	Outstanding at December 31, 2013				1,875,000
	Warrants Outstanding Table:
		Stock Warrants as of December 31, 2013
		Exercise				Warrants			Remaining		Warrants
		Price				Granted			Life (Years)		Exercisable
	$0.10						1,875,000		0.54	1,500,000
	Common Stock Options
	Since inception, the Company has issued options to purchase shares of the Company’s common stock to employees and consultants as compensation for services rendered. A summary of the Company’s options activity for the three months ended December 31, 2013 is provided below.
	Option awards with performance and service conditions
	On February 28, 2013, we granted to Mr. Medley a three-year non-qualified stock option to purchase up to 1,600,000 shares of our common stock at an exercise price equal to $0.10 per share, which was the closing market price of our common stock on February 28, 2013 (i.e., the date of grant).  The option will vest and become exercisable only if, and to the extent, the Company achieves the following milestones related to the Company’s trademark products (“Davi Products”):  (i) 400,000 shares of the option vested on the date that a recent licensee commercially releases Davi Products in Asia; (ii) 400,000 shares of the option will vest when certain licensed sales of Davi Products exceed $2,000,000; (iii) 400,000 shares of the option will vest when certain licensed sales of Davi Products exceed $5,000,000; and (iv) 400,000 shares of the option will vest on the date that we commercially launch any Davi Product in the U.S., other than on our website; provided, in each case, that Mr. Medley remains in our continuous employ through such vesting date.
	Option awards with no performance or service requirements
	On June 24, 2013, we granted to Mr. Medley a fully vested, non-qualified stock option to purchase up to 720,000 shares of our common stock any time before September 30, 2015 at an exercise price equal to $0.10 per share, which was the closing market price of our common stock on June 24, 2013 (i.e., the date of grant).
	On August 8, 2013, we granted to a consultant a fully vested, five-year non-qualified stock option to purchase up to 1,000,000 shares of our common stock at an exercise price equal to $0.10 per share, which was the closing market price of our common stock on August 8, 2013 (i.e., the date of grant).
	The fair value of these 3,320,000 options was estimated using the Black-Scholes option pricing model based on the following assumptions: expected dividend yield 0%, expected volatility 229% - 338%, risk-free interest rate 0.69% - 1.36% and expected life of 27 – 60 months.
			Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)	Grant Date Fair Value
	Outstanding at September 30, 2013		3,320,000		$0.10		3.06	$325,260
	Options granted		-		-		-	-
	Options exercised		-		-		-	-
	Options cancelled/ forfeited/ expired		-		-		-	-
	Outstanding at December 31, 2013		3,320,000		$0.10		2.8	$325,260
	Exercisable at December 31, 2013		2,520,000		$0.10		3.01	$290,964
	Compensation expense recognized for the above noted awards for the three months ended December 31, 2013 amounted to $28,567 and is included in stock based compensation in the accompanying statement of operations. Unamortized compensation cost for these awards amounted to $34,296 and will be amortized over the remaining vesting term of the option awards.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES	'
	Note 6 COMMITMENTS
	As of January 18, 2011, the Company entered into a lease with Resco LP, a California limited partnership for the office that the Company is leasing. Under the lease, the Company occupies approximately 1,500 square feet of office space at 9426-9428 Dayton Way, Beverly Hills, California. The lease term expires on January 31, 2016, unless terminated earlier in accordance with the lease. The Company’s monthly rent expense under the lease is approximately $5,700 per month, plus payments of approximately $1,000 per month for common area operating expenses. The Company has the option to extend the term of the lease by two additional years.
	At December 31, 2013, aggregate future minimum payments under the lease (including common area operating expense) is as follows:
	Fiscal year 2014	$	62,463
	Fiscal year 2015		85,225
	Fiscal year 2016		28,687
	Total	$	176,375
	Lease expense for the three months ended December 31, 2013 and 2012 were approximately $21,000 and $18,000, respectively.
	From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect our financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect us due to legal costs and expenses, diversion of management attention and other factors. We expense legal costs in the period incurred. We cannot assure you that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against us in the future, and these matters could relate to prior, current or future transactions or events. We are not currently a party to any litigation.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	Note 7 SUBSEQUENT EVENTS
	From January 2011 until September 30, 2013, we provided the chain of Peninsula Hotels with our Davi branded in-room skin care and related amenities. The Peninsula Hotel chain purchased our Davi branded products directly from our manufacturer and paid us a fee for each product purchased. Effective October 1, 2013, the agreement to provide such products to the Peninsula Hotels was terminated.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	In the opinion of management, the accompanying unaudited interim financial statements contain all adjustments necessary to present fairly the Company’s financial position as of December 31, 2013, and the results of operations and cash flows for the three months ended December 31, 2013 and 2012. The adjustments made are of a normal recurring nature. The accompanying unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The operating results for the three months ended December 31, 2013 are not necessarily indicative of the results that may be expected for the year ending September 30, 2014. The accompanying unaudited financial statements should be read in conjunction with the audited financial statements for the year ended September 30, 2013, which are included in our Annual Report on Form 10-K, and the "risk factors" described therein.
Reclassifications	'
	Reclassifications
	For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the financial statement presentation used in fiscal 2014. These reclassifications have no impact on net loss.

EQUITY_Tables

EQUITY (Tables)	3 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stock Option Activity Table	'
			Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)	Grant Date Fair Value
	Outstanding at September 30, 2013		3,320,000		$0.10		3.06	$325,260
	Options granted		-		-		-	-
	Options exercised		-		-		-	-
	Options cancelled/ forfeited/ expired		-		-		-	-
	Outstanding at December 31, 2013		3,320,000		$0.10		2.8	$325,260
	Exercisable at December 31, 2013		2,520,000		$0.10		3.01	$290,964
Warrant Activity Table	'
	Warrant Activity Table:
				Number of
				Warrants
	Outstanding at September 30, 2013				1,875,000
	Warrants exercised				-
	Warrants granted				-
	Warrants expired				-
	Outstanding at December 31, 2013				1,875,000
Warrants Outstanding Table	'
	Warrants Outstanding Table:
		Stock Warrants as of December 31, 2013
		Exercise				Warrants			Remaining		Warrants
		Price				Granted			Life (Years)		Exercisable
	$0.10						1,875,000		0.54	1,500,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Tables	'
Future minimum rental payments	'
	At December 31, 2013, aggregate future minimum payments under the lease (including common area operating expense) is as follows:
	Fiscal year 2014	$	62,463
	Fiscal year 2015		85,225
	Fiscal year 2016		28,687
	Total	$	176,375

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Text) (USD $)	24 Months Ended
	Mar. 11, 2015	Dec. 31, 2013	Sep. 30, 2013
Accounts payable - related party	'	$127,900	$119,500
Consultant Monthly Compensation	$5,000	'	'

CUSTOMER_CONCENTRATIONS_Detail

CUSTOMER CONCENTRATIONS (Details Text) (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Percent of sales from largest customer	0.84	0.71
Accounts receivable from largest customer	$70,000	'

EQUITY_Details_Text

EQUITY (Details Text) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
	Aug. 31, 2011	Dec. 31, 2013	Sep. 30, 2013	Aug. 08, 2013	Jun. 24, 2013	Feb. 28, 2013
Equity [Abstract]	'	'	'	'	'	'
Common stock granted not issued, value	'	'	$75,010	'	'	'
Common stock granted not issued, shares	'	'	750,000	'	'	'
Common stock granted for services not issued, value	'	'	20,000	'	'	'
Common stock granted for services not issued, shares	'	'	200,000	'	'	'
Fair Value Assumptions Expected Dividend Rate	'	'	0.00%	'	'	'
Fair Value Assumptions Expected Volatility Rate Maximum	'	'	338.00%	'	'	'
Fair Value Assumptions Expected Volatility Rate Minimum	'	'	229.00%	'	'	'
Fair Value Assumptions Risk Free Interest Rate Maximum	'	'	1.36%	'	'	'
Fair Value Assumptions Risk Free Interest Rate Minimum	'	'	0.69%	'	'	'
Fair Value Assumptions Expected Term Maximum	'	'	'0 years 60 months	'	'	'
Fair Value Assumptions Expected Term Minimum	'	'	'0 years 27 months	'	'	'
Salary deferral options	'	'	'	'	720,000	'
Exercise price of salary deferral options	'	'	'	'	$0.10	'
Stock option expense	'	28,567	'	'	'	'
Unrecognized stock based compensation	'	$34,296	'	'	'	'
Maximum performance option	'	'	'	'	'	1,600,000
Exercise price of performance option	'	'	'	'	'	$0.10
Consultant options	'	'	'	1,000,000	'	'
Exercise price of consultant options	'	'	'	$0.10	'	'
Performance option vesting terms	'(i) 400,000 shares of the option vested on the date that a recent licensee commercially releases Davi Products in Asia; (ii) 400,000 shares of the option will vest when certain licensed sales of Davi Products exceed $2,000,000; (iii) 400,000 shares of the option will vest when certain licensed sales of Davi Products exceed $5,000,000; and (iv) 400,000 shares of the option will vest on the date that we commercially launch any Davi Product in the U.S., other than on our website; provided, in each case, that Mr. Medley remains in our continuous employ through such vesting date.	'	'	'	'	'

EQUITY_Warrant_Activity_Table_

EQUITY - Warrant Activity Table (Details)	3 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Warrants outstanding	1,875,000
Warrants exercised	0
Warrants granted	0
Warrants expired	0

EQUITY_Warrants_Outstanding_Ta

EQUITY - Warrants Outstanding Table (Details)	Dec. 31, 2013
Warrant Exercise Price	0.1
Warrants outstanding	1,875,000
Remaining life of warrant	'6 months 15 days
Warrants Exercisable: $0.10	1,500,000

EQUITY_Stock_Option_Activity_T

EQUITY - Stock Option Activity Table Text Block (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013
Notes to Financial Statements	'	'
Outstanding Options	3,320,000	3,320,000
Exercisable Options	2,520,000	2,120,000
Weighted Average Exercise Price of Outstanding Options	$0.10	$0.10
Weighted Exercise Price of Exercisable Options	$0.10	$0.10
Weighted Average Remaining Contractual Life (in years) of Outstanding Options	'2 years 9 months 21 days	'3 years 21 days
Weighted Average Remaining Contractual Life (in years) of Exercisable Options	'3 years	'
Grant Date Fair Value of Outstanding Options	$325,260	$325,260
Grant Date Fair Value of Exercisable Options	$290,964	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES - Lease (Details 1) (USD $)	Dec. 31, 2013
Commitments And Contingencies - Lease Details 1	'
Fiscal year 2014	$62,463
Fiscal year 2015	85,225
Fiscal year 2016	28,687
Total	$176,375

COMMITMENTS_AND_CONTINGENCIESD

COMMITMENTS AND CONTINGENCIES(Details Text) (USD $)	3 Months Ended		60 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2016
Monthly rental expense	'	'	$5,700
Monthly common area maintenance costs	'	'	1,000
Lease expense	$21,000	$18,000	'